Introduction
When activated by transmembrane ligands of the Delta and Jagged families, the Notch intracellular domain (NICD) is cleaved, translocates to the nucleus, binds to the DNA binding protein, recombination signal binding protein for immunoglobulin kappa J (RBPJ), and induces target gene expression. 1 In the vasculature, delta-like ligand 4 (Dll4)/Notch signalling controls arterial specification and angiogenic tip/stalk cell selection, 2 -5 and in mouse and zebrafish models, decreased Dll4/Notch function leads to direct connections between arteries and veins, or arteriovenous malformations (AVMs). 2,6 -9 Because Dll4/Notch signalling transcriptionally up-regulates the arterial endothelial marker, ephrinb2 (Efnb2), 10 and decreased Dll4/Notch signalling results in loss of Efnb2 and ectopic arterial expression of the venous marker, Ephb4, 2,6 -8,10 -13 AVMs resulting from decreased Dll4/Notch signalling are generally attributed to disruption of arterial-venous identity. Notch loss-offunction (Notch lof ) generates small calibre AVMs that are associated with thin, nearly atretic arteries. 6, 7, 14 Notch gain-of-function (Notchgof), which enhances Efnb2 and represses Ephb4, also results in AVMs in mice,2,6 -8, 10 -13 and human brain AVMs exhibit increased Notch signalling. 15, 16 AVMs associated with Notch gof involve enlarged arteries containing supernumerary endothelial cells, 8, 9, 11, 12, 17 suggesting that failed repulsion mediated by EfnB2/EphB4, which is required for segregation of venous and arterial cells in developing vessels, 18, 19 may be responsible for these AVMs. Thus, both Notch lof and Notch gof result in AVMs associated with disrupted arterial-venous identity, but the morphological † Present address: Behavioural Biology, Center for Behaviour and Neurosciences, University of Groningen, Groningen, The Netherlands.
characteristics of these AVMs are distinct, with low flow, small calibre shunts associated with Notch lof and high flow, large calibre shunts associated with Notch gof . Similar to Notch signalling, bone morphogenetic protein (BMP) signalling has also been implicated in AVM prevention. BMP ligands bind to a heterotetrameric complex of type I and type II serine/threonine kinase receptors; non-signalling type III receptors facilitate ligand binding. Upon complex formation, type II receptors phosphorylate type I receptors, which in turn phosphorylate Smad1, Smad5, and Smad9. Phosphorylated Smads bind to Smad4, translocate to the nucleus, and bind to DNA to regulate gene expression. 20 In humans, heterozygous loss of endoglin (ENG, encoding a type III receptor), activin receptor-like kinase 1 (ACVRL1 or ALK1, encoding a type I receptor), or SMAD4 results in hereditary haemorrhagic telangiectasia (HHT), a disease characterized by a predisposition to development of telangiectasias and AVMs. 21 -24 Alk1 mutant mice exhibit decreased Efnb2 expression in the dorsal aorta (DA), 25 and BMP9/ALK1 transcriptionally induces EFNB2 in cultured human umbilical artery endothelial cells, 13 suggesting that ALK1, similar to Notch, is required for arterial identity. Also like Notch, ALK1 has been implicated in maintenance of stalk cell identity. 26 Thus, ALK1 and Notch might function in a common pathway to control arterial and/or stalk cell identity and prevent AVMs. Several lines of evidence suggest that Notch and ALK1 interact in endothelial cells. Activation of either DLL4/Notch or BMP9/ALK1 in cultured endothelial cells enhances expression of canonical Notch targets HEY1, HEY2, and HES1, 13, 26, 27 and simultaneous activation of these pathways synergistically increases expression of HEY1 and HEY2.
26
A less dramatic effect on HEY2 expression is observed in response to combined stimulation by constitutively active Notch (NICD) and ALK1 (ALK1 CA ). 10 Induction of HEY1 and HEY2 by BMP9/ALK1 requires SMAD4 but not RBPJ, 26 and BMP9 induces SMAD1/5 binding to HEY1, HEY2, and HES1 promoters in cultured human umbilical vein endothelial cells (HUVECs). 28 These findings suggest that BMP9/ALK1 directly stimulates canonical Notch targets by a SMAD-dependent and NICD/ RBPJ-independent pathway. Notch and ALK1 additively induce VEGFR1, a stalk cell marker, and inhibit APELIN, a tip cell marker, and endothelial cells lacking ALK1, SMAD4, or HEY2 are more likely to be in the tip position. 26 Together, these results suggest that BMP9/ALK1/SMAD signalling induces canonical Notch targets independently of NICD/RBPJ and reinforces Notch-mediated acquisition of arterial identity and maintenance of stalk cell fate. Although Notch and ALK1 exhibit synergistic interactions with respect to Notch target gene expression in cultured endothelial cells, evidence for synergy is less compelling for phenotypic endpoints. Both NICD and ALK1
CA dampen endothelial cell sprouting, but simultaneous pathway activation shows no further effects, and inhibition of one pathway does not inhibit effects of activation of the other pathway. 13 Similarly, both ALK1 and Notch inhibition enhance VEGF-stimulated tube formation in HUVECs and increase vascular area in the postnatal retina; however, combined inhibition of these pathways shows less than additive effects. 26 Thus, the synergy between Notch and ALK1 in controlling gene expression may not directly translate to synergistic effects on endothelial cell behaviour.
To better understand the interaction between Notch and Alk1, we assayed Notch target gene expression and vascular phenotype in zebrafish embryos with altered Notch and/or Alk1 activity. Results demonstrate that Alk1 is not necessary for maintenance of Notch target genes or arterial identity in vivo. However, concomitant inhibition of Notch and Alk1 revealed context-dependent interactions, with cooperative maintenance of hey2 and efnb2a in the DA but opposing effects on hey2 and no effect on efnb2a in cranial arteries. In addition, we observed increased dll4 expression in both trunk and cranial arterial endothelium in the absence of Alk1 signalling, in contrast to the loss of expression observed with Notch inhibition. These molecular data suggested that AVMs in alk1 mutants might arise due to Notch gain-of-function; however, Notch activation failed to phenocopy and Notch inhibition failed to rescue AVMs associated with loss of alk1. Taken together, these data demonstrate that Notch and Alk1 exhibit context-specific and target-specific interactions in controlling Notch target gene expression in vivo, and that AVMs associated with Alk1 deficiency do not result from perturbations in Notch activity.
Methods
Additional details can be found in Supplementary material online. with mRFP-labelled endothelial cell membranes, was generated using a previously described construct. 31 
Zebrafish lines and maintenance

Morpholinos and drug treatments
In situ hybridization
Whole mount in situ hybridization and vibratome sectioning were carried out as described 30, 39 using an InSituPro VSi liquid handler (Intavis Inc., Chicago, IL, USA).
Confocal and two-photon imaging and image analysis
Fluorescence imaging was performed using a Leica TCS SP5 multiphoton/ confocal microscope (Leica Microsystems, Wetzlar, Germany) as previously described. 39 LAS AF software, version 3.0.0 build 8134, was used to measure fluorescence intensity in Tg(tp1:egfp) um14 embryos. Effects of Notch inhibition and alk1 mutation on forebrain and midbrain central artery sprouting at 36 hpf were analysed from confocal micrographs using Adobe Photoshop CS6.
Statistical analysis
GraphPad Prism v6.0 was used to analyse data using Student's t-test (fluorescence intensities) or one-way ANOVA followed by Tukey's post-hoc test (BCA areas, central artery sprouting). Significance was set at P , 0.05. 33 on a background of mRFP-labelled endothelial cells. Embryos were imaged at 36 hpf, a time point when Alk1 is active in cranial arterial endothelium. 39 Notch activity was weak to moderate in cranial arteries, including the first aortic arch (AA1), internal carotid artery (ICA), caudal division of the internal carotid artery (CaDI), optic artery (OA), and basal communicating artery (BCA) ( Figure 1A ). All of these arteries are alk1-positive at 36 hpf. 31 Notch activity was also detected in the alk1-negative posterior communicating segments (PCS) and metencephalic arteries (MtA), but was absent in cranial veins ( Figure 1A ). These data demonstrate that cranial vascular Notch activity is arterial-specific, and that all alk1-positive arteries have active Notch signalling. Next, we assayed cranial vessel expression of endogenous Notch targets. Hairy and enhancer of split (HES)-related proteins are transcriptional repressors that are induced by NICD/RBPJ, 42 and the HESrelated genes HES1, HEY1, and HEY2 are up-regulated by BMP9/ALK1 in cultured endothelial cells. 10, 26, 28 The zebrafish genome contains two hes1 paralogs, her6 and her9. 43 However, neither these genes nor hey1
were detectable in endothelium at 24 -36 hpf (data not shown). In contrast, hey2 was expressed in all alk1-positive cranial arteries at 36 hpf ( Figure 1B ). efnb2a, another Notch target, 10 as well as dll4, which encodes a Notch ligand that is positively regulated by Notch signalling, 44 -46 were also expressed in all alk1-positive cranial arteries at 36 hpf ( Figure 1B ). dll4 was additionally expressed in the alk1-negative PCS and MtA. These data demonstrate that Notch targets hey2, efnb2a, and dll4 are expressed in cranial arterial endothelium concomitant with active Alk1 signalling and are good candidates for cooperative regulation by Notch and Alk1.
3.2 Notch and Alk1 cooperatively regulate hey2 and efnb2a but oppositely regulate dll4 in the dorsal aorta
To investigate the interaction between Notch and Alk1 in the regulation of Notch targets in vivo, we assayed tp1:egfp, hey2, efnb2a, and dll4 in embryos with impaired Notch and/or Alk1 signalling. To inhibit Notch signalling, we treated embryos with 10 mmol/L LY411575, a gamma-secretase inhibitor, between 23 and 36 hpf. This time period brackets the critical time period of Alk1 function: alk1 is first detectable around 26 hpf, and alk1 mutation results in enlargement of cranial arteries by 32 hpf. 31 LY411575 treatment had no effect on heartbeat or blood flow but resulted in severe trunk curvature (data not shown) as expected in Notch-inhibited embryos.
2,4,47
Notch signalling is active in the zebrafish DA throughout embryonic development, 2, 5, 48 and despite no obvious requirement for Alk1, alk1 is indeed expressed in the DA as early as 26 hpf. 31 LY411575 treatment resulted in complete loss of DA tp1:egfp expression (Figure 2A ), demonstrating effective abrogation of NICD/RBPJ-mediated transcription. However, the effect of Notch inhibition on expression of endogenous Notch targets was variable. LY411575 treatment had no effect on hey2, moderately decreased efnb2a, and completely abolished dll4 (Figure 2A ). These observations agree with published data 2, 40 and suggest that among these DA genes, dll4 is most sensitive to perturbation of Notch signalling, whereas other pathways maintain hey2 and efnb2a in the absence of Notch. Next, we examined Notch target gene expression in the DA in alk1 ft09e mutants (Figure 2A ). alk1 mutation had no effect on expression of tp1:egfp, hey2, or efnb2a in the DA (Figure 2A) , demonstrating that Alk1 is not necessary for expression of these arterial-specific Notch targets or for acquisition of arterial identity. In contrast, dll4 expression was up-regulated in the DA in alk1 ft09e mutants (Figure 2A) . This observation was confirmed in alk1 y6 and alk1 s407 mutants and in alk1 morphants (Supplementary material online, Figure S1A ). Furthermore, endothelialspecific expression of alk1 CA (fli1a.ebs:alk1 CA -mCherry) dramatically repressed dll4 (Supplementary material online, Figure S1B ). These data suggest that Alk1 opposes Notch in dll4 regulation in the DA. Compared with Notch inhibition alone, combined alk1 ft09e mutation and Notch inhibition had no effect on tp1:egfp or dll4 expression (Figure 2A ), supporting the idea that Notch is required for expression of these genes. In contrast, concomitant abrogation of Alk1 and Notch signalling decreased hey2 and nearly eliminated efnb2a (Figure 2A ). hey2 results, originally obtained in LY411575-treated alk1 ft09e embryos,
were recapitulated in DAPT-treated alk1 y6 mutants and LY411575-treated alk1 morphants (data not shown). These findings suggest cooperative support of hey2 and efnb2a expression by Notch and Alk1 in the DA and agree with published data suggesting that both genes are regulated independently via NICD/RBPJ and ALK1/Smad1,5. We next examined regulation of Notch target genes in cranial arteries, which enlarge upstream of AVMs in alk1 mutants. LY411575 treatment abrogated tp1:egfp expression in cranial arterial endothelium and neural domains ( Figure 2B , Supplementary material online, Figure S2 ), as expected. However, whereas Notch inhibition dramatically decreased hey2 in cranial arterial endothelium, efnb2a was refractory to this treatment ( Figure 2B , Supplementary material online, Figure S2 ). These effects were different from those observed in the DA (Figure 2A) , suggesting context-specific gene regulation. LY411575 treatment eliminated arterial dll4 expression in cranial arteries, similar to the DA, but increased dll4 in neural tissues ( Figure 2B , Supplementary material online, Figure S2 ). These observations support the idea of a positive feedback loop specific to arterial endothelial cells in which Notch signalling directly regulates DLL4 expression. 40,44 -46 As in the DA, in cranial arteries tp1:egfp, hey2, and efnb2a were unaffected by alk1 mutation or knockdown, whereas dll4 was markedly up-regulated, and a fli1a.ebs:alk1 CA -mCherry transgene dramatically repressed dll4 ( Figure 2B, Supplementary material online, Figures S1C, D  and S2 ). Also similar to the DA, loss of alk1 failed to rescue abrogation of tp1:egfp or dll4 expression induced by LY411575 treatment ( Figure 2B, Supplementary material online, Figure S2 ). In contrast, hey2 and efnb2a behaved differently in the absence of both Notch and Alk1 signalling in trunk vs. cranial arterial endothelial domains. In cranial arteries, efnb2a expression proved refractory to combined loss of Notch and Alk1 signalling, whereas this same treatment increased hey2 expression compared with Notch inhibition alone ( Figure 2B , Supplementary material online, Figure S2 ). hey2 results, originally obtained in LY411575-treated alk1 ft09e embryos, were recapitulated in DAPTtreated alk1 y6 mutants and LY411575-treated alk1 morphants (Supplementary material online, Figure S3 ). These results suggest that neither Notch nor Alk1 is necessary for cranial arterial efnb2a expression, whereas Notch activates and Alk1 dampens hey2 expression in cranial arteries, with Alk1 acting either downstream of NICD or independently of Notch. These data support the notion that region-specific regulatory networks control arterial expression of Notch target genes. Effects of Notch and Alk1 manipulation on Notch target gene expression are summarized in Table 1 . In Tg(endo:N1ICD) embryos, the CaDIs developed and lumenized normally, but sprouting from the PMBC was impaired, with BCA/ PMBC connections delayed up to 8 h compared with wild-type [ Figure 3 , compare A-E, wt to F -J, Tg(endo:N1ICD); Supplementary material online, Movies S3 and S4]. Vascular morphology was variable in 36 hpf Tg(endo:N1ICD) embryos, with establishment of early alternative drainage connections (e.g. BCA to PCS/MtA, Figure 3G and H ) associated with relatively normal calibre vessels, and establishment of late connections associated with CaDI/BCA engorgement and enlargement ( Figure 3P and Q) . Regardless of 36 hpf phenotype, BCA area was not significantly increased compared with control at 48 hpf ( Figure 3S ), but all Tg(endo:N1ICD) embryos maintained at least one BCA/PMBC connection, resulting in a small calibre AVM ( Figure 3P ′ , Q ′ , T ).
Notch
Although the Tg(endo:N1ICD) phenotype bears some resemblance to the alk1 mutant phenotype, these phenotypes originate and progress differently. In Tg(endo:N1ICD) embryos, delayed venous sprouting compromises early cranial arterial drainage, resulting in variable changes in CaDI/BCA calibres and small AVMs stemming from persistent BCA/ PMBC connections ( Figure 3F Figure 3R , R ′ , S), most often between the BCA and PMBC. 30, 31, 39 Although the Tg(endo:N1ICD) phenotype decreases in severity over time ( Figure 3Q and Q ′ ), the alk1 mutant phenotype exacerbates over time ( Figure 3R and R ′ ), with progressive increases in vessel calibre both upstream and downstream of the AVM.
Notch activity is not required for AVM development in alk1 mutants
To further explore the role of enhanced Dll4/Notch in AVM development in the absence of Alk1 function, we inhibited Notch activity in alk1 mutants and assessed cranial vascular phenotype. First, we injected a splice-blocking dll4 morpholino 4 into alk1 y6 mutants. The morpholino generated an aberrant splice product that eliminated exon 3, decreased wild-type transcript to 37% of control, and resulted in intersegmental vessel hypersprouting 4, 40 in 60% of embryos (Supplementary material online, Figure S4 ). Wild-type dll4 morphants exhibited a small but significant increase in BCA area at 36 hpf ( Figure 4A , B and I) but normal cranial vessel morphology, with no AVMs, at 48 hpf ( Figure 4E , F and J ). dll4 knockdown failed to rescue increased BCA area (36 hpf) or cranial AVMs (48 hpf) in alk1 y6 mutants ( Figure 4C , D, and G -J ).
Because we could not achieve complete knockdown of dll4, we treated alk1 mutants with LY411575 (beginning at 23 hpf) to eliminate Notch activity and assessed cranial vascular phenotype at 36 and Distinct origins of Notch gof and Alk1lof AVMs 48 hpf ( Figure 5 ). In DMSO-treated wild-type embryos, the anterior central arteries (CtAs) 49 sprouted as the BCA/PMBC connection regressed: one or two sprouts emerged from more anterior aspects of each PMBC and migrated medially, with sprouts interacting ipsilaterally but not contralaterally and ultimately connecting to the BCA by 36 hpf ( Figure 5A ). Notch inhibition in wild-type embryos had no effect on the CaDI/BCA but caused hypersprouting in the PMBC-derived CtAs at 36 hpf, with significant increases in number of PMBC-derived sprouts, connections to the BCA, branch points, and contralateral sprout connections ( Figure 5B , Supplementary material online, Figure S5A , A ′ , B, B
′ and E-H).
In contrast to Notch-inhibited embryos, DMSO-treated alk1 mutants exhibited enlarged CaDIs/BCAs at 36 hpf, as previously reported, 30, 31, 39 but PMBC-derived CtAs were unaffected ( Figure 5C , Supplementary material online, Figure S5C , C ′ , D, D ′ and E -H ). Notchinhibited alk1 mutants were indistinguishable from DMSO-treated alk1 mutants in terms of increased BCA calibre at 36 hpf ( Figure 5C , D, and I). At 48 hpf, LY411575 treatment decreased PCS calibre in both wildtype and alk1 mutant embryos but failed to rescue alk1 mutant AVMs ( Figure 5E -H and J ). Furthermore, despite enhanced dll4 expression, Notch signalling, as quantified by mean BCA EGFP fluorescence intensity in Tg(tp1:egfp) um14 embryos, was unchanged in alk1 morphants compared with control (Supplementary material online, Figure S6 ). These data support dll4 morphant data and suggest that enhanced Dll4/Notch signalling does not underlie AVM development in the absence of alk1.
Although Notch inhibition failed to rescue the alk1 mutant phenotype, alk1 mutation dampened Notch inhibitor-induced effects on CtAs, decreasing number of PMBC-derived sprouts, number of connections to the BCA, and CtA branch points to levels between wildtype DMSO-treated and wild-type LY411575-treated embryos ( Figure 5A -D, Supplementary material online, Figure S5 ). However, effects did not achieve statistical significance. Further studies are required to determine whether this result reflects a genetic interaction between Alk1 and Notch pathways or an effect of altered vascular haemodynamics.
Discussion
Our results in zebrafish embryos demonstrate context-specific effects of Notch signalling on arterial endothelial gene expression. Although Notch inhibition abrogated transcription of a synthetic Notch reporter and endogenous dll4 in both trunk and cranial arteries, other arterial Notch targets were less sensitive to Notch inhibition, suggesting that additional control elements sustain expression of these genes in the absence of Notch. Furthermore, Notch sensitivity of particular genes showed regional variation, suggesting unique regulatory mechanisms in different vascular beds. These data suggest that context-specific regulation, which may be lost or dampened in cultured endothelial cells, plays an important role in the control of Notch target gene expression in vivo.
Based on published work demonstrating cooperative interactions between DLL4/Notch and BMP9/ALK1 in enhancing arterial Notch target gene expression in cultured endothelial cells, 26 we had anticipated that combined Notch and Alk1 inhibition might additively if not synergistically decrease Notch target gene expression and impair arterial specification. However, abrogation of Alk1 signalling failed to decrease expression of Notch targets or disrupt arterial (hey2, efnb2a, dll4) or venous (data not shown) identity, and we uncovered only minor cooperative interactions between Alk1 and Notch, with both contributing to maintenance of efnb2a and hey2 expression in trunk but not cranial arteries. Furthermore, we uncovered opposing roles of Notch and Alk1 in expression of the Notch target and arterial marker, dll4. Although dll4 is up-regulated in the zebrafish DA in the absence of blood flow, 50 lack of blood flow cannot account for increased dll4 in alk1 mutants: blood flow remains strong in alk1 mutants at 36 hpf, with only a subtle redistribution of flow towards cranial vessels. 31 Together with previous data demonstrating increased cxcr4a and decreased edn1 in the absence of blood flow or alk1 expression, 31 these data support the idea that Alk1 mediates a flow-based signal that controls expression of a subset of arterial genes. It is also possible that dll4 up-regulation in the absence of alk1 might be attributed to the loss of the Smad1/5 target, id1. In the DA, id1 is down-regulated in the absence of alk1 or blood flow (data not shown), and ID1 stabilizes HES1 (Her6 in zebrafish), which in turn represses DLL4. 51, 52 Therefore, decreased Id1 might decrease Her6, thereby resulting in increased dll4. However, we were unable to detect her6 in zebrafish arterial endothelial cells by in situ hybridization. In addition to the unanticipated opposing effects of Notch and Alk1 on dll4 expression, we demonstrated a paradoxical interaction with respect to cranial arterial hey2 regulation, with loss of alk1 restoring hey2 to near control levels in Notch-inhibited embryos. This finding suggests that Alk1 may repress hey2 in cranial arterial endothelial cells either downstream of NICD cleavage or via an independent mechanism. Although it is possible that enhanced blood flow through enlarged, Figure 6 Cranial vessel architecture resulting from Alk1 and/or Notch manipulation. alk1 mutants develop enlarged cranial arteries (red) that drain through an aberrantly retained connection (purple) to major primitive drainage veins (blue alk1-dependent vessels might increase hey2 expression, this seems unlikely given that hey2 expression is unchanged in alk1 mutants with intact Notch signalling ( 8, 9, 11, 12, 17 Therefore, our finding that Alk1 inhibited dll4 expression initially suggested to us that increased Notch signalling might contribute to AVMs in alk1 mutants. However, multiple lines of evidence fail to support this hypothesis. First, although ectopic endothelial expression of N1ICD results in small cranial AVMs involving the same vessels as in alk1 mutants, the origin and progression of these AVMs differs dramatically. The primary defect leading to AVMs in N1ICD-expressing embryos is delayed venous-derived sprouting, whereas the primary defect in alk1 mutants is increased endothelial cell number in and calibre of upstream arteries. 31 Differences in the spatiotemporal expression of fli1a-driven N1ICD vs. alk1 limit the utility of our approach; however, we would expect that earlier N1ICD expression would cause an even more pronounced arterial phenotype if enhanced arterial Notch signalling could serve as a proxy for arterial alk1 loss. Secondly, neither dll4 knockdown nor Notch inhibition rescues alk1 mutant AVMs. Thirdly, despite increased dll4 expression, we failed to detect increased canonical Notch activity in alk1 mutants. Together, these results suggest that AVMs arise independently in Notch gof and Alk1 lof embryos ( Figure 6 ).
Although AVMs initiate via independent mechanisms in Notch gof and Alk1 lof embryos, both represent retention of normally transient BCA/ PMBC connections. In alk1 mutants, maintenance of BCA/PMBC connections occurs as an adaptive response to increased shear stress caused by enlargement of upstream arteries. 31 In Notch gof embryos, impaired venous-derived sprouting delays CaDI/BCA drainage, which likely alters cranial vascular haemodynamics and affects remodelling. Thus, an adaptive response to altered haemodynamics, downstream of independent primary molecular and cellular defects, may be a unifying factor in the development of Notch gof and Alk1 lof AVMs.
Although we failed to rescue vascular defects in alk1 mutants via Notch inhibition, we partially rescued CtA hypersprouting defects in Notch-inhibited embryos via alk1 mutation, suggesting some interaction between Notch and Alk1 in the cranial vasculature. It is possible that restored hey2 expression in the absence of both Notch and Alk1 signalling might contribute to this phenomenon, as knockdown of HEY2 enhances sprouting in cultured HUVECs. 26 However, whether these observations represent a true genetic interaction or a response to changes in vascular haemodynamics remains to be determined. In summary, our in vivo analysis of Notch and Alk1 signalling demonstrates gene-specific and context-specific interactions, with examples of both cooperative and antagonistic control of gene expression. However, results fail to support the idea that these pathways interact synergistically to control Notch target genes, program arterial identity, and prevent AVMs.
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